Merck KGaA, Pfizer's Lung Cancer Drug Flunks Late-Stage Trial By Sam | February 15, 2018 Detailed results from the JAVELIN Lung 200 trial will be submitted for presentation at an upcoming medical congress. Source: BioSpace Posted in BioPharma